This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Statistics and Research Methods  • Humanities  • Medicine and the Media  • Journalology/ Peer Review/ Authorship  • Medical Ethics  • Adverse Effects  • Alert me on articles by topic

The Adverse Effects of Industry Influence

Catherine D. DeAngelis, MD, MPH; Phil B. Fontanarosa, MD, MBA

JAMA. 2008;299(15):1833-1835.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The profession of medicine, in every aspect—clinical, education, and research—has been inundated with profound influence from the pharmaceutical and medical device industries. This has occurred because physicians have allowed it to happen, and it is time to stop.

Two articles^1-2 in this issue of JAMA provide a glimpse of one company's apparent misrepresentation of research data and its manipulation of clinical research articles and clinical reviews; such information and articles influence the education and clinical practice of physicians and other health professionals. The direct influence of for-profit companies on education^3-6 and clinical practice^7-8 has been well documented, so this Editorial deals primarily with clinical research.

The articles by Ross and colleagues¹ and by Psaty and Kronmal² document how one company, Merck & Co Inc, apparently manipulated dozens of publications to promote one of its products. But make no mistake—the manipulation . . . [Full Text of this Article]

Author Affiliations: Dr DeAngelis is Editor in Chief (cathy.deangelis@jama-archives.org) and Dr Fontanarosa is Executive Deputy Editor, JAMA.

RELATED ARTICLES

Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation
Joseph S. Ross, Kevin P. Hill, David S. Egilman, and Harlan M. Krumholz
JAMA. 2008;299(15):1800-1812.
ABSTRACT | FULL TEXT  

Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation
Bruce M. Psaty and Richard A. Kronmal
JAMA. 2008;299(15):1813-1817.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Should the drug industry work with key opinion leaders? Yes
Buckwell
BMJ 2008;336:1404-1404.
FULL TEXT